Continuing Preclinical Development of PPCM Vaginal Contraceptive MPT to IND
PPCM 阴道避孕药 MPT 至 IND 的持续临床前开发
基本信息
- 批准号:9889971
- 负责人:
- 金额:$ 98.48万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-05-05 至 2022-04-30
- 项目状态:已结题
- 来源:
- 关键词:Atopobium vaginaeBindingBiological AssayBone MarrowCharacteristicsChlamydia trachomatisClinical TrialsClinical Trials DesignContraceptive AgentsCyclic GMPDataDevelopmentDoseEconomicsEpidemicFeedbackFertilizationFormulationFundingFutureGelGrantGuidelinesHIVHerpes Simplex InfectionsHigh PrevalenceHumanHyaluronanIn VitroIncidenceInfection preventionLeadMedicalMicronucleus TestsNational Institute of Allergy and Infectious DiseaseNational Institute of Child Health and Human DevelopmentNeisseria gonorrhoeaeOralPharmaceutical PreparationsPharmacologic SubstancePhasePhase I Clinical TrialsPhase I/II Clinical TrialPhase I/II TrialPhase II Clinical TrialsPlacebosPlasmaPreclinical TestingPregnancyPreventionPrevention trialProductionProtocols documentationRattusResourcesSafetySeminal fluidServicesSexually Transmitted DiseasesSimplexvirusSmall Business Innovation Research GrantSpecific qualifier valueTechnologyToxicologyUnited StatesVaginaVaginal GelValidationVirus DiseasesWomanWorkanalytical methodanimal efficacybasecervicovaginalcommercializationcondomscontraceptive efficacydesignefficacy studygenotoxicityhuman tissueimprovedin vitro Assayin vivomanufacturing processmouse modelnovelnovel therapeuticspathogenphase 1 designspreclinical developmentpreventproduct developmentprogramsprophylacticresponsescale upsocialstemtrendunintended pregnancyvirology
项目摘要
Women in all economic, social, and cultural circumstances suffer from high rates of unplanned pregnancy, along with a high prevalence and incidence of sexually transmitted diseases. Trends in the United States and lesser developed economies are going in the wrong direction. The availability of a single multipurpose prevention product (MPT) that prevents both unplanned pregnancy and one or more of the most prevalent sexually transmitted diseases is a priority for both NICHD and NIAID. The development of Yaso-GEL, a vaginal gel formulation, will provide one of the first MPT products offering both pregnancy and STI protection, one that is easy to obtain and to use, that does not require medical services. In addition, Yaso-GEL is applied vaginally pre-coitally, has pre-fertilization contraceptive action, is non-hormonal and non-systemic. These characteristics avoid many safety concerns of current contraceptive users. The primary purpose of this Phase 2B grant is to complete CMC and toxicology studies required by FDA to submit an IND for Yaso-GEL. Secondarily, based on in vitro data, we wish to study the prophylactic potential of Yaso-GEL against two common sexually transmitted infections in cutting edge murine models. We are developing a new drug, polyphenylene carboxymethylene (PPCM) in a vaginal contraceptive gel (Yaso-GEL) as a multipurpose prevention technology (MPT) under R44HD092206. In preclinical testing, PPCM inhibits a broad spectrum of sexually transmitted infections (STIs) including Neisseria gonorrhoeae (Ng), Chlamydia trachomatis (Ct), Herpes simplex virus (HSV) and human immunodeficiency virus (HIV), in addition to having contraceptive activity. Under this grant, we will complete the work needed to open our IND. This includes: a) scale up Yaso- GEL under cGMP, fill applicators for clinical trials and establish a 3-year stability study; b) complete a toxicology study in rats as a second species; c) complete the last genotoxicity study; d) validate the bioassay in human cervicovaginal secretions and plasma; e) design Phase I and Phase 2 clinical trials for safety and contraceptive efficacy, utilizing a new ex vivo assay of contraceptive activity to establish optimal dose response; f) submit the IND. Secondarily, Yaso-GEL will be evaluated in murine models for prevention of infection with Neisseria gonorrhoeae (Ng) and Chlamydia trachomatis (Ct). If effective, future clinical trials may be conducted to evaluate prevention of these important STI pathogens in humans.
在所有经济、社会和文化环境中的妇女都遭受着高比率的非计划怀孕,同时沿着性传播疾病的高流行率和发病率。美国和欠发达经济体的趋势正在朝着错误的方向发展。提供单一的多用途预防产品(MPT),防止意外怀孕和一种或多种最流行的性传播疾病,是NICHD和NIAID的优先事项。Yaso-GEL是一种阴道凝胶制剂,其开发将成为首批提供妊娠和性传播感染保护的MPT产品之一,这种产品易于获得和使用,不需要医疗服务。此外,Yaso-GEL在性交前阴道应用,具有受精前避孕作用,是非激素和非全身性的。这些特点避免了目前避孕药具使用者的许多安全问题。该2B期资助的主要目的是完成FDA要求的CMC和毒理学研究,以提交Yaso-GEL的IND。其次,基于体外数据,我们希望研究Yaso-GEL在尖端小鼠模型中对两种常见性传播感染的预防潜力。我们正在开发一种新的药物,聚亚苯基羧基亚甲基(PPCM)在阴道避孕凝胶(Yaso-GEL)作为一种多用途预防技术(MPT),根据R44 HD 092206。在临床前试验中,PPCM抑制广谱性传播感染(STI),包括淋病奈瑟菌(Ng)、沙眼衣原体(Ct)、单纯疱疹病毒(HSV)和人类免疫缺陷病毒(HIV),此外还具有避孕活性。在此资助下,我们将完成启动IND所需的工作,包括:a)根据cGMP扩大Yaso- GEL的规模,为临床试验提供申请人,并建立3年的稳定性研究; B)完成大鼠作为第二物种的毒理学研究; c)完成最后的遗传毒性研究; d)验证人类宫颈阴道分泌物和血浆中的生物测定; e)设计I期和II期临床试验的安全性和避孕功效,利用新的避孕活性的体外测定来建立最佳剂量反应; f)提交IND。其次,将在小鼠模型中评价Yaso-GEL预防淋病奈瑟菌(Ng)和沙眼衣原体(Ct)感染的效果。如果有效,未来可能会进行临床试验,以评估这些重要的性病病原体在人类中的预防。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Polyphenylene carboxymethylene (PPCM) microbicide repurposed as antiviral against SARS-CoV-2. Proof of concept in primary human undifferentiated epithelial cells.
- DOI:10.1016/j.antiviral.2021.105162
- 发表时间:2021-10
- 期刊:
- 影响因子:7.6
- 作者:Escaffre O;Freiberg AN
- 通讯作者:Freiberg AN
Evaluation of the novel vaginal contraceptive agent PPCM in preclinical studies using sperm hyaluronan binding and acrosome status assays.
- DOI:10.1111/andr.13110
- 发表时间:2022-03
- 期刊:
- 影响因子:4.5
- 作者:North BB;Weitzel MB;Waller DP;Birch WX;Feathergill KA;Birch LA;De Jonge CJ;Prins GS
- 通讯作者:Prins GS
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ann E. Jerse其他文献
Gonococcal PorB: a multifaceted modulator of host immune responses
淋球菌孔蛋白B:宿主免疫反应的多面调节因子
- DOI:
10.1016/j.tim.2023.10.002 - 发表时间:
2024-04-01 - 期刊:
- 影响因子:14.900
- 作者:
Rebekah A. Jones;Ann E. Jerse;Christoph M. Tang - 通讯作者:
Christoph M. Tang
emNeisseria gonorrhoeae/em Coinfection during emChlamydia muridarum/em Genital Latency Does Not Modulate Murine Vaginal Bacterial Shedding
淋病奈瑟菌/鼠衣原体生殖器潜伏期间的合并感染不会调节小鼠阴道细菌脱落
- DOI:
10.1128/spectrum.04500-22 - 发表时间:
2023-05-18 - 期刊:
- 影响因子:3.800
- 作者:
Delia Onorini;Cory Ann Leonard;Regenia Phillips Campbell;Barbara Prähauser;Theresa Pesch;Robert V. Schoborg;Ann E. Jerse;Bernadetta Tarigan;Nicole Borel - 通讯作者:
Nicole Borel
Ann E. Jerse的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ann E. Jerse', 18)}}的其他基金
The Gonorrhea Vaccine Cooperative Research Center
淋病疫苗合作研究中心
- 批准号:
10362587 - 财政年份:2019
- 资助金额:
$ 98.48万 - 项目类别:
The Gonorrhea Vaccine Cooperative Research Center
淋病疫苗合作研究中心
- 批准号:
10588233 - 财政年份:2019
- 资助金额:
$ 98.48万 - 项目类别:
The Atlantic Coast Sexually Transmitted Infection Cooperative Research Center (AC
大西洋海岸性传播感染合作研究中心(AC
- 批准号:
9316484 - 财政年份:2014
- 资助金额:
$ 98.48万 - 项目类别:
The Atlantic Coast Sexually Transmitted Infection Cooperative Research Center (AC
大西洋海岸性传播感染合作研究中心(AC
- 批准号:
8769562 - 财政年份:2014
- 资助金额:
$ 98.48万 - 项目类别:
2014 International Pathogenic Neisseria Conference
2014年国际致病性奈瑟菌会议
- 批准号:
8785926 - 财政年份:2014
- 资助金额:
$ 98.48万 - 项目类别:
相似国自然基金
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
- 批准号:32170319
- 批准年份:2021
- 资助金额:58.00 万元
- 项目类别:面上项目
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
- 批准号:
- 批准年份:2021
- 资助金额:58 万元
- 项目类别:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
- 批准号:31672538
- 批准年份:2016
- 资助金额:62.0 万元
- 项目类别:面上项目
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
- 批准号:31372080
- 批准年份:2013
- 资助金额:80.0 万元
- 项目类别:面上项目
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
- 批准号:81172529
- 批准年份:2011
- 资助金额:58.0 万元
- 项目类别:面上项目
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
- 批准号:81070952
- 批准年份:2010
- 资助金额:35.0 万元
- 项目类别:面上项目
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
- 批准号:30672361
- 批准年份:2006
- 资助金额:24.0 万元
- 项目类别:面上项目
相似海外基金
Collaborative Research: NSF-BSF: How cell adhesion molecules control neuronal circuit wiring: Binding affinities, binding availability and sub-cellular localization
合作研究:NSF-BSF:细胞粘附分子如何控制神经元电路布线:结合亲和力、结合可用性和亚细胞定位
- 批准号:
2321481 - 财政年份:2024
- 资助金额:
$ 98.48万 - 项目类别:
Continuing Grant
Collaborative Research: NSF-BSF: How cell adhesion molecules control neuronal circuit wiring: Binding affinities, binding availability and sub-cellular localization
合作研究:NSF-BSF:细胞粘附分子如何控制神经元电路布线:结合亲和力、结合可用性和亚细胞定位
- 批准号:
2321480 - 财政年份:2024
- 资助金额:
$ 98.48万 - 项目类别:
Continuing Grant
Alkane transformations through binding to metals
通过与金属结合进行烷烃转化
- 批准号:
DP240103289 - 财政年份:2024
- 资助金额:
$ 98.48万 - 项目类别:
Discovery Projects
NPBactID - Differential binding of peptoid functionalized nanoparticles to bacteria for identifying specific strains
NPBactID - 类肽功能化纳米粒子与细菌的差异结合,用于识别特定菌株
- 批准号:
EP/Y029542/1 - 财政年份:2024
- 资助金额:
$ 98.48万 - 项目类别:
Fellowship
Conformations of musk odorants and their binding to human musk receptors
麝香气味剂的构象及其与人类麝香受体的结合
- 批准号:
EP/X039420/1 - 财政年份:2024
- 资助金额:
$ 98.48万 - 项目类别:
Research Grant
Postdoctoral Fellowship: OPP-PRF: Understanding the Role of Specific Iron-binding Organic Ligands in Governing Iron Biogeochemistry in the Southern Ocean
博士后奖学金:OPP-PRF:了解特定铁结合有机配体在控制南大洋铁生物地球化学中的作用
- 批准号:
2317664 - 财政年份:2024
- 资助金额:
$ 98.48万 - 项目类别:
Standard Grant
I-Corps: Translation Potential of Real-time, Ultrasensitive Electrical Transduction of Biological Binding Events for Pathogen and Disease Detection
I-Corps:生物结合事件的实时、超灵敏电转导在病原体和疾病检测中的转化潜力
- 批准号:
2419915 - 财政年份:2024
- 资助金额:
$ 98.48万 - 项目类别:
Standard Grant
The roles of a universally conserved DNA-and RNA-binding domain in controlling MRSA virulence and antibiotic resistance
普遍保守的 DNA 和 RNA 结合域在控制 MRSA 毒力和抗生素耐药性中的作用
- 批准号:
MR/Y013131/1 - 财政年份:2024
- 资助金额:
$ 98.48万 - 项目类别:
Research Grant
CRII: OAC: Development of a modular framework for the modeling of peptide and protein binding to membranes
CRII:OAC:开发用于模拟肽和蛋白质与膜结合的模块化框架
- 批准号:
2347997 - 财政年份:2024
- 资助金额:
$ 98.48万 - 项目类别:
Standard Grant
How lipid binding proteins shape the activity of nuclear hormone receptors
脂质结合蛋白如何影响核激素受体的活性
- 批准号:
DP240103141 - 财政年份:2024
- 资助金额:
$ 98.48万 - 项目类别:
Discovery Projects